Effects of smoking on the lower respiratory tract microbiome in mice

Rui Zhang¹, Ling Chen², Lei Cao¹, Kang-jie Li¹, Yao Huang³, Xiao-qian Luan¹ and Ge Li²*

Abstract

Background: Recent studies break with traditional opinion that the lower respiratory tract is sterile, and increasingly focus on the lung microbiome and disease. Smoking, as an important etiology of inflammatory lung disease, was considered as a factor influencing lung microbiome variations in our study, and we aimed to study the effect of smoking on inflammation and microbial diversity and community.

Methods: Forty male mice were selected and randomly divided into a smoking and a non-smoking group. Mice in the smoking group were exposed to smoke smog for 2 h/day for 90 days. Blood and lung tissues were obtained after the experiment, and ELISA was used to measure interleukin-6 and C reactive protein concentrations. 16S rRNA gene quantification and sequencing technology were used to compare microbial diversity and community between the two groups. SAS 9.1 and R software were used to analyze the data.

Results: Thirty-six mice survived, and the weight of the smoking group increased more slowly than that of the non-smoking group. Denser inflammation and congestion were observed in the lungs of the smoking mice compared with the non-smoking group. Higher microbial diversity was observed in the smoking group, and Enterobacter, Acidimicrobiales, norank, and Caulobacteraceae Unclassified genus were significantly more abundant in the non-smoking group ($P < 0.001$).

Conclusions: Smoking altered microbial diversities and communities in the lower respiratory tract of mice. Microbial variation should be considered in future studies focusing on smoking-induced inflammatory disease.

Keywords: Lower respiratory tract, Microbiome, Inflammation, Smoking, Mice

Background

Historically, the lower respiratory tract (LRT) was considered sterile because culture-based techniques failed to detect microbes in the LRT [1–3]. This opinion was changed by recent detection of bacteria in the LRT by newly developed molecular techniques, particularly the widely used high-throughput sequencing of amplicons of the 16S rRNA gene [4, 5]. Approximately 10 years ago, Maciej Dancewicz et al. [6] reported bacterial colonization of the bronchi with gram-positive cocci in approximately 30% of lung cancer patients. Markus Hilty et al. [7] described a characteristic microbial flora in the bronchial tree that was strikingly distinct between healthy and asthmatic individuals. These findings were milestones in the path to appreciation of the LRT microbiome. Nowadays, the LRT is generally understood to house microbes, but the origin and pathogenicity thereof are still disputed. Most studies [8–12] consider that microbes in the LRT originate in the upper respiratory tract (URT), including the oral and nasal cavities, and colonize the LRT by air inhalation of air, microaspiration, and direct dispersion along mucosal surfaces [11–13]. However, a few studies proposed that microbes in the LRT were introduced by contamination from the URT when bronchoscopes and bronchoalveolar lavage were used to sample the lung and bronchial tree [7, 14, 15]. Accordingly, sampling and detection methods are critically important for accurate assessment of the LRT microbiome.

Smoking is one of the key causes of morbidity and mortality worldwide [16]. It is widely understood to be associated with lung cancer (LC), asthma, chronic obstructive pulmonary disease (COPD), hearing loss, tooth loss, cardiovascular disease, and periodontal disease.
Moreover, smoking may increase the risk of social problems, including poor self-rated health, hospital use, health-related behaviors (suicide, violence, and drinking) [20–22]. Although it is agreed that smoking is harmful to human health, the mechanism remains unclear. Inflammation plays a major role in the development of smoking-induced disease [23–25]. In the mouse model, smoking induces chronic inflammation in the airways [24], worsens lung inflammation [25], and increases the expression of tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1), and interleukin-6 (IL-6) [26, 27]. Recently, with the proposition of microbiome existing in the gut and oral cavity, increasing number of studies focus on the microbiome, as a new etiology, that may play a crucial role in the development of inflammatory disease [28–30]. Theoretically, microbiome is closely associated with the incidence of inflammatory disease, but this statement is still controversial. The mechanism by which smoking serves as a commonly etiology of inflammatory lung disease remains unclear. Since the presence of a LRT microbiome is now partially accepted and the role thereof in the development of lung disease is now understood to be important, we hypothesize that the microbiome may play a critical role in the mechanisms underlying smoking-induced inflammatory lung disease.

Our study uses a mouse model to explore variation in microbiome diversity and composition within the LRT as a result of smoking, while also assessing the incidence of inflammation. To avoid contamination of the microbiome, we dissected lung tissue from mice, and used PCR was to detect the microbiome in the LRT by URT microbes, we dissected lung tissue fixed in 10% paraformaldehyde into lung tissue. We measured the levels of inflammatory mediators, including IL-6 and C-reactive protein (CRP), using enzyme linked immunosorbent assay (ELISA). Lung tissues were cut and stained with hematoxylin and eosin (H&E) to assess inflammation.

**Methods**

The animal study was approved by the Experimental Animal Ethics Committee of Chongqing Medical University. All mice were treated in conformance to animal welfare standards.

**Study design**

Eight-week-old male Kunming mice weighing 20–22 g were purchased from the Experimental Animal Center, Chongqing Medical University. A total of 40 mice were divided into a smoking group and non-smoking group using a randomized block design with 20 mice per group. Mice in the smoking group were exposed to smoke for 2 h (14 ‘Five Cattle’ cigarettes) / day for 90 days [31]. Mice in the non-smoking group received no smoke. Water and food availability was the same in the two groups. Body weight was recorded twice a week, and activity and food intake were measured daily. After 90 days, all mice were decapitated, blood was collected, and the chest cavity dissected. Right lung tissue was stored at −80 °C until microbiome sequencing was conducted; left lung tissue was stored in 10% paraformaldehyde in the dark until pathological slides were made using H&E stain. Blood was centrifuged at 3500 rpm for 10 min immediately after collection, and the serum thus obtained was stored at −80 °C for ELISA.

**Elisa**

IL-6 (pg/ml) and CRP (ng/ml) were quantified using Mouse IL-6 ELISA kits (Cat.#:CK-E20012M, 48 T) and CRP ELISA kit (Cat.#:CK-E30459M, 48 T), respectively. Kits were taken from the refrigerator and kept at room temperature (20–25 °C) for 20–30 min before use. All standards and samples were added in duplicate to the Microelisa Stripplate; 50 μl of standard was added to the standard well, and 10 μl of the test sample and 40 μl of sample diluent were added to the sample well. Then, 100 μl of HRP-conjugate reagent was added to each well, which was covered with an adhesive strip and incubated for 60 min at 37 °C. Each well was then aspirated and washed five times, each with 400 μl of wash solution. Chromogen solution A and Chromogen solution B (50 μl) were added to each well and incubated for 15 min at 37 °C in incubators protected from light. Stop solution was then added to each well, and optical density (O.D.) measured at 415 nm using the standard microplate reader (ELx808). A standard curve was generated using six standard concentrations, and used to calculate the standard concentration of each sample according to its O.D. value.

**H&E stains**

Lung tissue fixed in 10% paraformaldehyde was sliced (7 μm), washed with flowing water for 6 h, and then dehydrated progressively by immersion in increasingly concentrated ethanol (70% for 1.5 h, 83% 1.5 h, 95% 1 h, 95% 0.5 h, 100% 10 min, 100% 5 min, and finally xylenes for 20 min, and then 30 min). The slices were then put in paraffin with soft wax for 4 h, hard wax for 4.5 h, and then embedded. The lung tissue was then cut into 5-μm sections, and stained with H&E. Staining steps were as follows: first, dehydrating with xylene (two steps of 10 min each), and then with decreasing concentrations of ethanol (100, 95%, and then 70% for 1 min each). Second, staining with mordant (10 s) and hematoxylin (7 min), washing with flowing water (3 min), and staining with eosin (1 min). Third, dehydration with 100% ethanol (1 s, repeated a total of four times). Finally, sections were cleared using xylene (20 min repeated a total of 4 times), and then mounted in neutral resin. Slides were viewed and photographed at 400× magnification on an Olympus.
BX40 microscope. Pathological score was applied to evaluate the degree of lung injury using a 5-point scale from four parameters (congestion, edema, inflammation, and hemorrhage) based on severity (0 = absent/appearing to be normal, 1 = light, 2 = moderate, 3 = strong, 4 = intense) [32].

DNA extraction and PCR amplification
Microbial DNA was extracted, amplified, and sequenced according to a previously published protocol [33–35]. DNA was extracted from lung samples with the use of E.Z.N.A.® Soil DNA Kit (Omega Bio-tek, Norcross, GA, U.S.). The V4-V5 region of the bacterial 16S ribosomal RNA gene was amplified by PCR with the following cycles: initial denaturing at 95 °C for 2 min, and then 25 cycles of denaturation at 95 °C for 30 s, annealing at 55 °C for 30 s, and extension at 72 °C for 30 s, followed by a final extension at 72 °C for 5 min. We used the primers 515F 5′-barcode-GTGCCAGCMGCCGCGG-3′ and 907R 5′-CCGTCAATTCTMTTTRAGTTT-3′, where the barcode is an eight-base sequence unique to each sample. PCR reactions were performed in triplicate, with each 20-μL mixture containing 4 μL of 5 × FastPfu Buffer, 2 μL of 2.5 mM dNTPs, 0.8 μL of each primer (5 μM), 0.4 μL of FastPfu Polymerase, and 10 ng of template DNA. Amplicons were extracted from 2% agarose gels and purified using the AxyPrep DNA Gel Extraction Kit (Axygen Biosciences, Union City, CA, U.S.) according to the manufacturer’s instructions and quantified using QuantiFluor™-ST (Promega, U.S.).

Library construction and sequencing
Purified PCR products were quantified using Qubit®3.0 (Life Invitrogen) and every twenty-four amplicons whose barcodes were different were mixed equally. The pooled

Fig. 1 Variations in body weight of the mice over the course of the study. The lines represent Means, the error bars represent Standard Deviations (SDs)

Fig. 2 Plasma Interleukin-6 (IL-6) concentrations (pg/ml) in the blood of mice compared between smoking and non-smoking mice. Medians (central lines), inter-quartile ranges (boxes) and minima and maxima (whiskers)
DNA product was used to construct an Illumina Pair-End library following Illumina’s genomic DNA library preparation procedure. Then the amplicon library was paired-end sequenced (2 × 250) on an Illumina HiSeq platform according to the manufacturer’s instructions.

**Processing of sequencing data**

Raw fastq files were demultiplexed, quality-filtered using QIIME (version 1.17) with the following criteria: (1) The 250 base pair (bp) reads were truncated at any site receiving an average quality score of < 20 over a 10-bp sliding window, discarding the truncated reads that were shorter than 50 bp. (2) Exact barcode matching: 2-nucleotide mismatches in primer matching, reads containing ambiguous characters were removed. (3) Only sequences that overlapped longer than 10 bp were assembled according to their overlap sequence. Reads that could not be assembled were discarded.

**Statistical analysis**

SAS 9.1 software was used to compare inflammatory mediators and weight gain between mice in the smoking and non-smoking groups. With the Standard Operating
Procedure indicating that a minimum sequence length of 250 bp should be used to MiSeq sequence [36, 37], sequenced data were processed and analyzed with the use of Mothur v.1.21.1 [36]. P < 0.05 was considered as indicating statistical significance. Operational Taxonomic Units (OTUs) were clustered with 97% similarity cutoff with the use of UPARSE 7.1 and UCHIME was used to identify and remove chimeric sequences. The phylogenetic affiliation of each 16S rRNA gene sequence was analyzed using RDP Classifier (http://rdp.cme.msu.edu/)

### Table 1: Histological score of lung tissues in mice

|                  | Smoking group | Non-smoking group |
|------------------|---------------|-------------------|
| Congestion<sup>a</sup> | 2.09 ± 1.30   | 0.90 ± 0.54       |
| Edema            | 1.27 ± 0.90   | 0.91 ± 0.70       |
| Inflammation<sup>a</sup> | 2.27 ± 1.27   | 0.91 ± 0.70       |
| Hemorrhage<sup>a</sup> | 1.36 ± 0.81   | 0.73 ± 0.47       |
| Total<sup>a</sup>  | 1.75 ± 1.14   | 0.86 ± 0.59       |

Values are mean ± SD. *P* < 0.05 between smoking and non-smoking groups

![Fig. 5 a](image1.png) Rarefaction curve for microbial communities in lung tissue of the two groups. **b** Rank–abundance distribution curve for microbial communities in lung tissue of the two groups.
against the silva (SSU129) 16S rRNA database using a confidence threshold of 70% [38].

Rarefaction analysis based on Mothur v.1.21.1 [36] was conducted to reveal diversity indices, including Chao, ACE, Shannon diversity and PD indices. Beta diversity analysis was performed using UniFrac [39] to compare the results of the principal component analysis (PCA) using the community ecology package, R-forge (Vegan 2.0 package) was used to generate a PCA figure). The Vegan package in R was also used for the Mantel test, Redundancy analysis (RDA), and Heatmap Figs. R Package VennDiagram was used to make Venn diagrams. We performed clustering on genera obtained from the RDP Classifier by means of the complete linkage hierarchical clustering technique using the R package HCLUST. To examine dissimilarities in community composition, we performed PCoA in QIIME. PCoA, where a distance matrix is used to

![Figure 6a](image1.png)  
**Fig. 6a** The Shannon diversity indices compared between smoking and non-smoking mice.

![Figure 6b](image2.png)  
**Fig. 6b** The PD diversity indices compared between smoking and non-smoking mice. Medians (central lines), inter-quartile ranges (boxes) and minima and maxima (whiskers)
plot n samples in \((n - 1)\) -dimensional space, was used to compare groups of samples based on unweighted and weighted UniFrac distance metrics.

**Results**

**Body weights and survival**

Four mice died during the experiment (two each in the smoking and non-smoking groups). The remaining 36 mice (18 mice in each group) were used for the data analysis. Mice in the smoking and non-smoking groups were active and ate well during the experiment. However, the body mass of the smoking group increased more slowly than that of the non-smoking group (Fig. 1), with differences in mass gain between the groups particularly evident from the second experimental week on. Repeated measures analysis of variance reported significant time (\(F = 78.436, P = 0.000 < 0.05\)) and time*group (\(F = 4.825, P = 0.004 < 0.05\)) effects, confirming both significant mass gain over time, and a significant difference in mass gain between the smoking and non-smoking groups.

**Between-group differences in lung inflammation**

The concentrations of IL-6 and CRP in blood, as measured by ELISA, are depicted in Figs. 2 and 3, respectively. Median and inter-quartile ranges (M, Q) were used to demonstrate the level of IL-6 and CRP in both smoking and non-smoking mice. Neither IL-6 (pg/ml) nor CPR differed between the smoking group and non-smoking group (\(P > 0.05\)).

Denser inflammation and congestion were observed in the lungs of the smoking mice compared with the non-smoking group (H&E staining result shown in Fig. 4). The total histological score was higher in smoking mice than in non-smoking mice (Table 1).

**Microbial richness and diversity**

A total of 857,201 microbial sequences and 322,076,731 base pairs (bp) with average length 375.7238889 were detected in smoking group, and 848,798 sequences and 318,896,085 bp with average length 375.7094444 were detected in the non-smoking group. These values did not differ between the groups.

Rarefaction curves (Fig. 5) ascended sharply when the number of reads sampled was less than 10,000, and leveled off when the number of reads sampled exceeded 10,000, indicating that the sequencing depth was sufficient to reflect 97% of the microbiome species present. Rank-abundance curves showed that the microbiome of lung tissue was of great richness and evenness (Fig. 10).

Shannon diversity indices of the microbiome are shown in Fig. 6a, and PD indices in Fig. 6b. The PD index indicated that the alpha-diversity in the smoking group was significantly higher than that in the
Fig. 8  a The microbiome of lower respiratory tract resolved to the phylum level. b The microbiome of lower respiratory tract resolved to the genus level. c Heatmap resolved to the genus level.
non-smoking group (37.62 ± 3.56 vs 34.96 ± 3.33, *P* < 0.05).

**Microbial community composition**

Two-dimensional principal component analysis (2D PCA, Fig. 7) showed that the composition of the LRT microbiome was similar in both smoking and non-smoking groups. The microbiome in the smoking group showed a classification trend, whereas a clustering trend was observed in the non-smoking group, suggesting some differences between the groups. More variation was observed in smoking group.

The LRT microbiome resolved to phylum and genus level is shown in Fig. 8 and b. At the phylum level, Proteobacteria and Firmicutes were the dominant members, with Proteobacteria and Firmicutes (24.00%) dominating in both the smoking group (61.64 and 24.00% respectively), and the non-smoking group (62.96 and 23.51%). At the genus level, *Halo- monas* dominated (20.01% in the smoking group, and 21.98% in the non-smoking group). Heatmap shows a data matrix where coloring gives an overview of the numeric differences. The heatmap at the genus level, which represents the differences in abundance of the top 50 LRT genera in the two groups, is shown in Fig. 8.

**LRT microbial differential analysis**

The OTU distribution of the LRT microbiome reveals 601 unique OTUs in the smoking group, 422 in the non-smoking group, and 856 shared between both groups (Fig. 9).

Linear discriminant analysis effect size (LEfSe) analyses were conducted to detect the differences between the smoking and non-smoking group at the OTU, genus, or higher level. The cladogram (Fig. 10) and linear discriminant analysis (LDA, Fig. 10) showed differences in bacterial abundance between the smoking and non-smoking groups. Only genera with LDA scores > 2.0 and *P* values < 0.05 are showed in Fig. 10. A total of 47 genera, 24 in the smoking group and 23 in the non-smoking group, differed statistically between the two groups. The most unique microbial taxa in the smoking group were *Trichococcus*, *Escherichia-Shigella*, and Oxalobacteraceae, and those in the non-smoking group were *Oceanospirillales*, *Lactobacillus*, and Lactobacillaceae.

The STAMP differential genus analysis shows differences in relative abundance at the genus level between the smoking and non-smoking groups (Fig. 11). In total, there were 29 differentiating genera in the smoking and non-smoking groups, and *Enterobacter, Acidimicrobiales_norank, Caulobacteraceae_Unclassified* were the most statistically significant differentiating taxa in the two groups, and above genus were at higher abundance in the non-smoking group than in the smoking group.

Wilcoxon tests comparing taxon abundance at the genus level showed that *Enterobacter, Phyllobacteriaceae_ uncultured, Raoultella*, and Caulobacteraceae_Unclassified occurred in higher abundance in the non-smoking group than in the smoking group (Table 2). STAMP analyses showed similar results.

**Discussion**

Recent studies revealing the diversity and dynamic nature of the microbiome harbored in the LRT [40, 41] have challenged traditional thoughts that the LRT is sterile. The severity, progression, exacerbation, and mortality of disease [42–48], and the incidence and development of inflammation in the LRT are closely associated with community structure and diversity of the LRT microbiome. Moreover, even in the healthy body, immunity is significantly related to the lung microbiome [49].

Tobacco, the most common addictive substance worldwide, kills more than 7 million people annually (WHO Report on the Global Tobacco Epidemic, 2017) [50]. In 2015, 20.7% of all adults aged over 15 years were current smokers, with concomitantly higher risks of developing cancers or heart and lung disease [51–53]. Our study aimed to deepen the understanding of the relationship between smoking, inflammation, and the LRT microbiome that underlies many of these pathologies. By sampling the lung tissues of mice with dissection, we avoided microbial contamination by the URT.

As sex and race may influence microbial community structure and diversity [10], we selected only male Kunming mice. In 2008, Gualano et al. [25] reported that mice lost weight temporarily during smoke exposure, but regained this when smoking ceased. We report depression of weight gain in mice exposed to smoke, which nonetheless were active and ate well during smoke exposure.
Fig. 10a The lefse cladogram showing differences between bacterial abundance in the smoking and non-smoking groups. Red represents the critical microbiome in the smoking group, and green represents that in the non-smoking group. 

b The linear discriminant analysis showing the differences between bacterial abundance in the smoking and non-smoking groups. Red represents the critical microbiome in the smoking group, and green represents that in the non-smoking group.
exposure. The smoking-induced weight depression that we report was therefore not a result of depressed appetite. Smoking has a pro-inflammatory effect [54], so we measured the serum levels of IL-6 and CRP using ELISA. IL-6 is a pro-inflammatory mediator, which plays a critical role in stimulation of the downstream of inflammatory response [55], and may reflect the severity of disease [56]. CRP, as an important biomarker of systemic inflammation, may also reflect the severity of disease [57–59]. Although no significant inter-group differences in IL-6 and CRP levels were observed, our results indicated that IL-6 and CRP levels tend to increase in mice with smoke exposure. We showed greater density of H&E stain due to congestion in lung tissue, suggesting increased inflammatory cell infiltration in the smoking group. The abovementioned results demonstrated that smoke-exposure caused inflammation, and further proved that smoking induced the alteration of immune system function.

We found that the PD diversity index of the LRT microbiome was significantly higher in smoke-exposed mice than in non-smoking mice. Generally, microbial diversity decreases with disease progression, and smoking or lung disease are associated with lower microbial diversity [47, 60–63]. Smoking has been reported to lower microbial diversity of buccal mucosa [62]. Both the severity of COPD and airway inflammation have been associated with revealed that bacterial diversity loss [60, 63]. Conversely, lung microbial diversity may be unaffected by smoking [10] or by COPD [64]. Our finding that microbial diversity was higher in the smoking group may indicate that smoke exposure increases the risk of bacterial infection, thereby increasing microbial diversity.

Lower clustering in the microbiome of smoking mice than that in non-smoking mice shows that smoking may alter community structure in the LRT microbiome, but different mice strains appear to show different effects. In our study, the Firmicutes and Proteobacteria phyla and Halomonas genus were similar in both smoking and non-smoking groups, which was inconsistent with previous studies suggesting that lower microbial diversity favors Proteobacteria abundance [14, 65]. Interestingly, we observed no relationship between microbial diversity and Proteobacteria abundance.

LEfSe revealed that dominant bacterial groups differed between smoke-exposed and non-smoking mice. Trichococcus, Escherichia/Shigella, and Oxalobacteraceae were
Table 2 Genus differences in abundance between the smoking and non-smoking groups

| Genus                        | Smoking Mean | Smoking S.D. | Non-smoking Mean | Non-smoking S.D. | p-value |
|------------------------------|--------------|--------------|------------------|------------------|---------|
| Enterobacter                 | 0.008177     | 0.005258     | 0.018444         | 0.00483          | < 0.0001 |
| Escherichia-Shigella         | 0.008657     | 0.00667      | 0.004092         | 0.004879         | < 0.01  |
| Proteus                      | 0.001254     | 0.00154      | 0.000273         | 0.00056          | < 0.01  |
| Acidimicrobiales_norank     | 0.000267     | 0.000347     | 2.41E-05         | 8.71E-05         | < 0.01  |
| Phyllobacteriaceae_uncultured| 0.00775      | 0.003756     | 0.010989         | 0.003684         | < 0.01  |
| Raoultella                   | 0.005131     | 0.002501     | 0.007025         | 0.002235         | < 0.01  |
| Mitochondria_norank         | 5.56E-06     | 1.72E-05     | 0.000338         | 0.000568         | < 0.01  |
| Planctomycetaceae_uncultured| 0.00857      | 0.00107      | 0.000147         | 0.000459         | < 0.01  |
| Pullulanibacillus            | 0.001354     | 0.001972     | 0.000265         | 0.000651         | < 0.05  |
| Caulobacteraceae_Unclassified| 0.005294    | 0.002533     | 0.007739         | 0.002541         | < 0.01  |
| Marvinbryantia               | 0.000516     | 0.000724     | 2.78E-05         | 0.000118         | < 0.05  |
| Alloprevotella               | 0.000998     | 0.001237     | 0.000304         | 0.000578         | < 0.05  |
| Brevibacillus                | 0.001616     | 0.001114     | 0.010148         | 0.022133         | < 0.05  |
| Geobacter                    | 0.010113     | 0.003727     | 0.013178         | 0.003238         | < 0.05  |
| Lactobacillus                | 0.049345     | 0.012194     | 0.060961         | 0.015105         | < 0.05  |
| Marine Group III_norank     | 9.27E-06     | 1.54E-05     | 0                | 0                | < 0.05  |
| Jatrophahabitans             | 6.31E-05     | 0.000136     | 0                | 0                | < 0.05  |
| TK10_norank                 | 7.23E-05     | 0.000148     | 0                | 0                | < 0.05  |
| Catenisphaera               | 0            | 0            | 3.90E-05         | 9.11E-05         | < 0.05  |
| Pseudochrobactrum            | 0.000176     | 0.000354     | 0                | 0                | < 0.05  |
| Planomicrobiurn              | 0.00059      | 0.001098     | 7.42E-06         | 1.83E-05         | < 0.05  |
| Subdoligranum                | 0.001343     | 0.001082     | 0.00631          | 0.00978          | < 0.05  |
| Diaphorobacter               | 0.000924     | 0.001252     | 0.001369         | 0.000859         | < 0.05  |
| Ktedonobacteraceae_uncultured| 0.000447     | 0.000522     | 0.000121         | 0.000371         | < 0.05  |
| Trichococcus                 | 0.009978     | 0.034947     | 0.00907          | 0.001714         | < 0.05  |
| Corynebacterium              | 3.52E-05     | 0.000104     | 0.000354         | 0.000794         | < 0.05  |
| Macroccus                    | 0.000377     | 0.000632     | 0.000143         | 0.000598         | < 0.05  |
| Mesorhizobium                | 0.010714     | 0.004223     | 0.013191         | 0.002912         | < 0.05  |
| Dyadobacter                  | 0.000603     | 0.000763     | 0.000232         | 0.000488         | < 0.05  |
| DA111_norank                 | 0.000432     | 0.000541     | 0.000106         | 0.000199         | < 0.05  |
| Chloroplast_norank           | 0.0055       | 0.004292     | 0.015309         | 0.030561         | < 0.05  |
| Brachybacterium              | 0.000141     | 0.000464     | 0.000163         | 0.000233         | < 0.05  |
| Jeotgalicoccus               | 4.82E-05     | 0.000205     | 0.000508         | 0.00091          | < 0.05  |
| Porphyromonas                | 0.000924     | 0.000988     | 0.000345         | 0.000574         | < 0.05  |
| Paucimonas                   | 0.000427     | 0.000794     | 3.34E-05         | 0.000134         | < 0.05  |
| Mucispirillum                | 0            | 0            | 0.000477         | 0.00104          | < 0.05  |
| Paludibacter                 | 6.68E-05     | 0.000162     | 0                | 0                | < 0.05  |
| Pasteurella                  | 0            | 0            | 9.83E-05         | 0.000218         | < 0.05  |
| Varibacter                   | 0            | 0            | 0.000232         | 0.000516         | < 0.05  |
| Kluvera                      | 0.015941     | 0.005622     | 0.01941          | 0.005691         | < 0.05  |
| Nitrosomonadaceae_uncultured | 0.02154      | 0.001431     | 0.001495         | 0.002391         | < 0.05  |
| Pedobacter                   | 0.00071      | 0.000912     | 0.000191         | 0.000306         | < 0.05  |
| Nesterenkonia                | 0.010996     | 0.003809     | 0.013003         | 0.002724         | < 0.05  |
| Lactococcus                  | 0.002298     | 0.001321     | 0.001493         | 0.001189         | < 0.05  |
the most unique microbes in the smoke exposed group, whereas these were Oceanospirillales, Lactobacillus, and Lactobacillaceae in the non-smoking group. Furthermore, totally 29 differentiating genera between smoking and non-smoking groups, and Enterobacter, Acidimicrobiales_norank, and Caulobacteraceae_Unclassified at the genus level were more abundant in the non-smoking group than in the smoking group. Differential analysis results proved that smoke exposure alters the microbial structure and community in the mouse LRT, which is consistent with the findings of previous studies. Smoke may increase both the risk of inflammation, and LRT microbial diversity and abundance, but it is unclear whether smoking induces inflammation and then the microbiome is altered, or smoking induces microbiome changes and then inflammation occurs. We plan to explore the order of inflammation and microbial changes after smoke exposure in future.

In addition, a microbiome was detected in two blood samples from smoking mice to explore the microbiome in blood. We found an unexpected result that there was a microbiome in blood, and that the Shannon index in lung tissue was higher than that in blood. In addition, higher Halomonas genus was noted in blood than in lung tissue, and less OTUs were noted in blood than in lung tissue. Although we only analyzed two blood samples, we could hypothesize that a microbiome existed in the whole body, and that its effect on the health are unclear.

Limitations
Although our study yielded novel insights, there still are some limitations. It is possible that the small sample size may have affected our results. And inclusion of female mice in a future study would address the effect of hormonal and gender-related differences on the LRT microbiome.

Conclusion
We found that smoking may increase the risk of inflammation, and most importantly probably increases the microbial diversity of the LRT in mice. We confirmed both the existence of a microbiome in the LRT, and the fact that smoking probably alters microbial diversities and communities within this microbiome. We hope our study provides new insights to direct further studies focusing on the microbiome of the LRT.

Abbreviations
CRP: C-reactive protein; ELISA: Enzyme Linked Immunosorbent Assay (ELISA); HE: Hematoxylin and Eosin; IL-6: Interleukin-6; LC: Lung Cancer; LRT: Lower Respiratory Tract; PCA: Principal components analysis; PCR: Polymerase Chain Reaction; RDA: Redundancy analysis

Acknowledgements
We give very special thanks to every team member to conduct this experiment.

Funding
Funding for this study was provided by The Experimental Teaching Center, Chongqing Medical University (Grant Number 201509), but they had no role in the study design, collection, analysis or interpretation of the data, writing the manuscript, or the decision to submit the paper for publication.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
RZ and GL designed the study and wrote the protocol. RZ conducted literature searches and provided summaries of previous research studies. RZ, LC, KL, YH and XL conducted the experiment. LC and RZ conducted the statistical analysis. RZ wrote the first draft of the manuscript and all authors contributed to and have approved the final manuscript.

Ethics approval and consent to participate
The study’s protocol and data collection procedure were approved by Chongqing Medical University (Reference Number 2018021).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Research Center for Medicine and Social Development, Collaborative Innovation Center of Social Risks Governance in Health, School of Public Health and Management, Chongqing Medical University, Chongqing 400016, China. 2The Center of Experimental Teaching Management, Chongqing Medical University, Chongqing 401331, China. 3First Clinical College, Chongqing Medical University, Chongqing 400016, China.

Received: 19 August 2018 Accepted: 30 November 2018
Published online: 14 December 2018

References
1. Laurenzi GA, Potter RT, Kass EH. Bacteriologic flora of the lower respiratory tract. N Engl J Med. 1961;265:1273–8.
2. Niederman MS, Sarois GA. Respiratory tract infections. Philadelphia: Lippincott Williams & Wilkins; 2005.
3. Pecora DV. A comparison of transtracheal aspiration with other methods of determining the bacterial flora of the lower respiratory tract. N Engl J Med. 1963;269:664–7.
4. Murphy TF, Brauer AL, Schifflacher AT, Seth S. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:266–72.
5. Dickson RP, Erb Downward JR, Freeman CM, Walker N, Scales BS, Beck JM, et al. Changes in the lung microbiome following lung transplantation include the emergence of two distinct pseudomonas species with distinct clinical associations. PLoS One. 2014;9(5):e97214.
6. Maciej D, Maria S, Mariusz B, Joanna S. Bronchial bacterial colonization in patients with lung cancer. Advances in Respiratory Medicine. 2009;27(3):242–7.
7. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, et al. Disordered microbial communities in asthmatic airways. PLoS One. 2010;5(1):1–9.
8. Gleeson K, Eggli DF, Maxwell SL. Quantitative aspiration during sleep in normal subjects. Chest. 1997;111(5):1266–72.
9. Huxley EJ, Vroslav J, Gray WR, Pierce AK. Pharyngeal aspiration in normal adults and patients with depressed consciousness. Am J Med. 1978;64(4):564–8.
10. Morris A, Beck JM, Schloss PD, Campbell TB, Crotthers K, Curtis JL, et al. Comparison of the respiratory microbiome in healthy non-smokers and smokers. Am J Respir Crit Care Med. 2013;187(10):1067–75.

11. Bowers RM, Sullivan AP, Costello EK, Collett JL Jr, Knight R, Fierer N. Sources of bacteria in outdoor air across cities in the midwestern United States. Appl Environ Microbiol. 2011;77(18):6350–6.

12. Bertolino V, Gandolfi I, Ambrosini R, Bestetti G, Innocente E, Rampazzo G, et al. Temporal variability and effect of environmental variables on airborne bacterial communities in an urban area of northern Italy. Appl Microbiol Biotechnol. 2013;97(14):6561–70.

13. Lighthart B. Mini-review of the concentration variations found in the aero-allergen atmospheric bacterial populations. Aerobiologia. 2000;16(17–16).

14. Erb-Downward JR, Thompson DL, Han MK, Freeman CM, McCloskey L, Schmidt LA, et al. Analysis of the Lung Microbiome in the “Healthy” Smoker and in COPD. PLoS ONE. 2011;6(2):1–12 15.

15. Charlson ES, Bittinger K, Haas AR, Fitzgerald AS, Frank I, Yadav A, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med. 2011;184:957–96.

16. American Cancer Society. Cancer facts and figures 2016. Atlanta: American Cancer Society; 2016.

17. Brant LJ, Gordon-Salant S, Pearson JD, Klein LI, Morell CH, Metter EJ, et al. Risk factors related to age-associated hearing loss in the speech frequencies. J Am Acad Audiol. 1996;7(3):152–60.

18. Costa MG, Serena M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2002;346:2445–54.

19. Billings J, Zeitel L, Lukomnik J, et al. Impact of socioeconomic status on hospital use in New York City. Health Aff. 1993;12:162–73.

20. Haines HM, Cynthia O, Perce D, Bourke L. Notwithstanding high prevalence of overweight and obesity, smoking remains the most important factor in poor self-rated health and hospital use in an Australian regional community. Aust MS Public Health. 2014;38(4):402–17.

21. Fleischer NL, Lozano P, Antillo Santillán E, Reyes-Miguel Sanchis, LM, Thresher JF. The impact of neighborhood violence and social cohesion on smoking behaviors among a cohort of smokers in Mexico. J Epidemiol Community Health. 2015;69(1):1083–90.

22. Lee J, Taneya V, Vassallo R. Cigarette smoking and inflammation: cellular and molecular mechanisms. J Dent Res. 2012;91(2):142–9.

23. Chung A, Tai I, Hae C, Wright JL. Tumor necrosis factor-alpha is central to acute cigarette smoke-induced inflammation and connective tissue breakdown. Am J Respir Crit Care Med. 2002;166:849–54.

24. Gualano RC, Hansen MJ, Vilhos R, Jones JE, Park-Jones RA, Deliyannis G, et al. Cigarette smoke worsens lung inflammation and repairs resolution of influenza infection in mice. Respir Res. 2009;8:53–69.

25. Vilhos R, Bozinoski S, Jones JE, Powell J, Gross J, Lilja A, et al. Differential proteome, immune response, and NF-kappaB induction profiles during lung inflammation induced by subchronic cigarette smoke exposure in mice. American journal of physiology. Lung cellular and molecular physiology. 2006;290(5):L931–L938.

26. Guerassimov A, Hashino Y, Takubo Y, Tucurco A, Yamamoto M, Ghezzo H, et al. The development of emphysema in cigarette smoke exposed mice is strain dependent. Am J Respir Crit Care Med. 2004;170(9):974–80.

27. Matsukawa K, Kanai T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol. 2015;37(1):47–62.

28. Granet C, Miossec P. Combination of the pro-inflammatory cytokines IL-1, TNF-alpha and IL-17 leads to enhanced expression and additional recruitment of AP-1 family members, Egr-1 and NF-kappaB in osteoblast-like cells. Cytokine. 2004;26(4):169–77.

29. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Lozupone CA, Turnbaugh PJ, et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc Natl Acad Sci U S A. 2011;108(Suppl 1):4516–22.

30. Kozich JJ, Westcott SL, Baxter NT, Klindt SK, Schloss PD. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Appl Environ Microbiol. 2013;79:1112–20.

31. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol. 2009;75:1531–41.

32. Amato KR, Yeoman CJ, Kent A, Righini N, Carbonero F, Estrada A, et al. Habitat degradation impacts black howler monkey (Alouatta pigra) gastrointestinal microorganisms. The ISME Journal. 2013;7:1344–53.

33. Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Appl Microbiol Biotechnol. 2013;97(14):6561–70.

34. Erb-Downward JR, Thompson DL, Han MK, Freeman CM, McCloskey L, Schmidt LA, et al. Analysis of the Lung Microbiome in the “Healthy” Smoker and in COPD. PLoS ONE. 2011;6(2):1–12 15.
57. Davé S, Van Dyke TE. The link between periodontal disease and cardiovascular disease is probably inflammation. Oral Dis. 2008;14:95–101.
58. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev. 2007;65:253–9.
59. Mendall MA, Patel P, Asante M, Ballam L, Morris J, Strachan DP, et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart. 1997;78:273–7.
60. Monsó E. Microbiome in chronic obstructive pulmonary disease. Annals Translation Medicine. 2017;5(12):251.
61. Molyneaux PL, Maher TM. The role of infection in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir Rev. 2013;22:576–81.
62. Yu GQ, Phillips S, Gail MH, Goedert JJ, Humphreys MS, Ravel J, et al. The effect of cigarette smoking on the oral and nasal microbiota. Microbiome. 2017;5:1–6.
63. Russell SL, Gold MJ, Willing BP, Thorson L, McNagny KM, Finlay BB. Perinatal antibiotic treatment affects murine microbiota, immune responses and allergic asthma. Gut Microbes. 2013;4(02):598–64.
64. Sze MA, Dimitriu PA, Hayashi S, Elliott WM, McDonough, JE, Gosselink J, et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(10):1073–80.
65. Huang YJ, Kim E, Cox MJ, Brodie EL, Brown R, Wiener-Kronish JP, et al. A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations. OMICS International. 2010;14:9–16.